-
Shandong Junxiu Biotechnology Secures RMB 45M in Series B Financing
•
Shandong Junxiu Biotechnology Co., Ltd, a China-based maker of implantable regenerative medicine devices, has raised RMB 45 million (USD 6.2 million) in a Series B financing round. The round was led by Shenzhen Capital Group, with participation from Qianhai FOF, Huantong Venture Capital, and other investors. The proceeds will be…
-
Brii Biosciences Reports Positive Phase I Results for HIV Treatments BRII-732 and BRII-778
•
China-based Brii Biosciences Limited (HKG: 2137) has published the latest results of two Phase I clinical studies assessing its long-acting BRII-732 and BRII-778, both being developed to treat HIV infection, in healthy subjects in the US. The results showed that both BRII-732 and BRII-778 produced good safety and tolerability profiles…
-
Bayer to Set Up Shenzhen Unit to Boost Women’s Healthcare in South China
•
Bayer’s (ETR: BAYN) women’s healthcare unit for the South China region is reportedly planning to establish a Shenzhen regional unit, tasked with product promotion in Shenzhen and southern Guangzhou. The move is designed to reinforce Bayer’s prescription drug strategy in China and expand its women’s healthcare segment, according to the…
-
GenScript’s Legend Biotech Reports USD 55M in Carvykti Sales
•
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has revealed that sales of its subsidiary company Legend Biotech Corporation’s (NASDAQ: LEGN) BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), reached USD 55 million as of September 30, 2022. The drug is being commercialized in the…
-
YiChang HEC ChangJiang Pharma’s Insulin Aspart Gains NMPA Approval
•
China-based firm YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that its in-house developed insulin aspart (specification 3ml: 300 units, refill) has been approved for marketing by the National Medical Products Administration (NMPA). This approval marks a significant milestone in the company’s efforts to expand its presence in…
-
Henlius Biotech’s Hanbeitai Gains NMPA Approval for Recurrent Glioblastoma
•
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that a supplementary Biologic License Application (sBLA) for its bevacizumab biosimilar, Hanbeitai, has been approved by the National Medical Products Administration (NMPA). The drug can now be used to treat recurrent glioblastoma (GBM), expanding its therapeutic applications in China. Previous Approvals and…
-
NHSA Responds to Proposal on Dental Implants’ Inclusion in NRDL
•
The National Healthcare Security Administration (NHSA) has responded to the No. 6184 suggestion from the 5th session of the 13th National People’s Congress regarding the inclusion of dental implants in the National Reimbursement Drug List (NRDL). The NHSA clarified that fixed and removable dentures are not covered by the NRDL,…
-
Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance
•
US giant Johnson & Johnson (J&J, NYSE: JNJ) released its Q3 2022 financial report, showing global sales growth of 1.9% year-on-year (YOY) in reported terms to USD 23.8 billion. However, operational sales, excluding acquisitions, divestitures, and currency impacts, grew by 8.2%. This performance prompted the company to maintain its 2022…
